natgillin/translations-raw huggingface dataset:
An isolated antibody that is capable of binding to the alloantigen HPA-1a and which does not significantly bind to the alloantigen HPA-1b, and that comprises at least one heavy chain variable region that comprises three CDRs and at least one light chain variable region that comprises three CDRs, wherein said light chain variable region comprises: 
Izolirano protutijelo koje se može vezati na aloantigen HPA-1a i koje se ne veže u značajnoj mjeri na aloantigen HPA-1b, te koje sadrži najmanje jedno varijabilno područje teškog lanca koje sadrži tri CDR i najmanje jedno varijabilno područje lakog lanca koje sadrži tri CDR, gdje navedeno varijabilno područje lakog lanca sadrži:
The antibody according to claim 1 or claim 2, wherein said antibody is a full length IgG antibody. 
Protutijelo u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačeno time što je navedeno protutijelo IgG protutijelo pune duljine.
The antibody according to claim 1 or claim 2, wherein said antibody is an antibody fragment, such as a Fab fragment or a F(ab')2 fragment. 
Protutijelo u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačeno time što je navedeno protutijelo fragment protutijela, poput fragmenta Fab ili fragmenta F(ab′)2.
A method for analysing for the presence or absence of HPA-1a in a sample that has been obtained from a subject, said method comprising the steps of 
Postupak analiziranja na prisutnost ili odsutnost HPA-1a u uzorku dobivenom iz subjekta, naznačen time što se navedeni postupak sastoji u koracima
analysing for the presence or absence of anti-HPA-1a antibody-HPA-1a (antigen) complexes, preferably said sample is a sample containing platelets. 
analiziranje na prisutnost ili odsutnost kompleksa protutijela protiv HPA-1a s HPA-1a (antigenom), gdje je po mogućnosti navedeni uzorak uzorak koji sadrži trombocite.
In vitro use of an antibody according to any one of claims 1 to 7 as a reference standard for quantifying anti-HPA-1a antibodies in a sample, preferably said sample is a whole blood sample or a plasma sample. 
Upotreba protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 7 in vitro, pri čemu je protutijelo referentni standard u kvantificiranju protutijela protiv HPA-1a u uzorku, gdje je po mogućnosti navedeni uzorak uzorak pune krvi ili uzorak plazme.
A bispecific antibody for use according to claim 1 or 3, wherein the subject is afflicted with a tumor that is resistant to, or incompletely responsive to (a) anti-CD20 monospecific therapy alone, or (b) rituximab monotherapy; 
Bispecifično antitijelo za primjenu prema patentnom zahtjevu 1 ili 3, naznačeno time što subjekt boluje od tumora koji je rezistentan na ili ne postiže potpun odgovor na (a) samostalnu terapiju protiv CD20 monospecifičnog antitijela ili (b) monoterapiju rituksimabom;
and/or wherein the subject has received an anti-CD20 monospecific antibody therapy at least 1 day to 1 year prior to the administration of the bispecific antibody. 
i/ili naznačeno time, što je subjekt primao terapiju protiv CD20 monospecifičnog antitijela najmanje 1 dan do 1 godinu prije primjene bispecifičnog antitijela.
exhibits decreased complement dependent cytotoxicity (CDC) compared to an antibody comprising a wild-type Fc domain, as measured in an in vitro cytotoxicity assay; 
ispoljava smanjenu citotoksičnost ovisnu o komplementu (engl. complement dependent cytotoxicity, CDC) u usporedbi s antitijelom koje sadrži Fc domenu divljeg tipa, kada se mjeri in vitro testom citotoksičnosti;
A compound of the formula: or a pharmaceutically acceptable salt thereof, for use in a method of reducing the effect of chemotherapy on healthy cells in a subject being treated for cyclin-dependent kinase 4/6 (CDK4/6) replication independent cancer or abnormal cell proliferation, wherein said healthy cells are hematopoietic stem cells, hematopoietic progenitor cells, or renal epithelial cells, the method comprising administering to the subject an effective amount of the compound. 
Spoj formule: ili njegova farmaceutski prihvatljiva sol, za upotrebu u postupku smanjenja efekta kemoterapije na zdravim stanicama kod subjekta koji se liječi od ciklin ovisne kinaze 4/6 (CDK4/6) replike samostalnoga karcinoma ili abnormalne proliferacije stanica, gdje su spomenute zdrave stanice matične hematopoetske stanice, hematopoetske progenitorne stanice, ili epitelne stanice bubrega, postupak obuhvaća davanje subjektu efektivne količine spoja.
The compound for use according to claim 1, wherein the compound is administered to the subject prior to treatment with a chemotherapeutic agent, during treatment with a chemotherapeutic agent, after exposure to a chemotherapeutic agent, or a combination thereof. 
Spoj za upotrebu prema zahtjevu 1, gdje se spoj daje subjektu prije tretmana s kemoterapeutskim agensom, u tijeku tretmana s kemoterapeutskim agensom, nakon izlaganja kemoterapeutskom agensu, ili njihovoj kombinaciji.
The compound or salt for use according to claim 5, wherein the cancer is small cell lung carcinoma and the at least one chemotherapeutic agent is selected from the group consisting of etoposide, cisplatin or carboplatin, or a combination thereof. 
Spoj ili sol za upotrebu prema zahtjevu 5, gdje je karcinom karcinom pluća malih stanica i bar jednan kemoterapeutski agens izabran iz grupe koja obuhvaća etopozid, cisplatin ili karboplatin, ili njihovu kombinaciju.
The compound or salt for use according to any one of claims 1 to 11, wherein at least 80% or more of the hematopoietic stem cells, hematopoietic progenitor cells, or renal epithelial cells in the subject return to or approach pre-treatment baseline cell-cycle activity in less than about 36 hours from the last administration of the compound in humans. 
Spoj ili sol za upotrebu prema bilo kojem od zahtjeva 1 do 11, gdje se bar 80% ili više matičnih hematopoetskih stanica, hematopoetskih progenitorskih stanica, ili epitelnih stanica bubrega u subjektu vrati ili pristupi osnovnoj aktivnosti staničnog ciklusa prije tretmana za manje od oko 36 sati od posljednjeg davanja spoja ljudima.
The compound or salt for use according to any one of claims 1 to 11, wherein the dissipation of the compound's or salt's CDK4/6 inhibitory effect occurs in less than 36 hours from the administration of the compound. 
Spoj ili sol za upotrebu prema bilo kojem od zahtjeva 1 do 11, gdje se razgradnja spoja ili soli CDK4/6 inhibitornog efekta događa u manje od 36 sati od davanja spoja.
determining a first Intra mode associated with a top neighbor block of a current block; 
određivanju prvog Intra moda povezanog s lijevim susjednim blokom trenutačnog bloka;
The polypeptide expression system of claim 1, wherein the P1Euk1 is a cytomegalovirus (CMV) promoter or a simian virus 40 (SV40) promoter. 
Polipeptidni ekspresijski sustav prema patentnom zahtjevu 1, naznačen time, da P1Euk1 i/ili P2Euk je promotor citomegalovirusa (CMV) ili promotor simijan virusa 40 (SV40).
The polypeptide expression system of claim 6, wherein the P1Prok1 is a selected from the group consisting of a PhoA promoter, a Tac promoter, a Lac, and a Tphac promoter. 
Polipeptidni ekspresijski sustav prema patentnom zahtjevu 1, naznačen time, da je P1Prok1 odabran iz skupine koja sadrži promotor PhoA, promotor Tac, Lac i promotor Tphac.
The polypeptide expression system of claim 6, wherein the ePPM1, further comprises a first nucleic acid sequence encoding a prokaryotic signal sequence (PSS11). The polypeptide expression system of claim 8, wherein the PSS11 is a heat-stable enterotoxin II (stII) signal sequence. 
Polipeptidni ekspresijski sustav prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time, da ePPM1 nadalje sadrži prvu sekvencu nukleinske kiseline koja kodira prokariotsku signalnu sekvencu (PSS11), preferirano s time, da je PSS11 izveden iz toplinski stabilnog gena enterotoksin II (STII).
A vector set comprising a first vector and a second vector, wherein the first and second vectors comprise the first and second nucleic acid molecules, respectively, of the polypeptide expression system of claim 1 . 
Komplet vektora koji sadrži prvi vektor i drugi vektor, naznačen time, da prvi i drugi vektor sadrže prvu odnosno drugu molekulu nukleinske kiseline polipeptidnog ekspresijskog sustava prema bilo kojem od patentnih zahtjeva 1 do 22.
A method comprising: 
Metoda koja se sastoji od:
The method of claim 1, further comprising emitting a series of audible beeps counting down the scrub period. 
Metoda prema patentnom zahtjevu 1, koja se dodatno sastoji od emitiranja niza zvučnih signala kojima se odbrojava vremensko razdoblje čišćenja.
The method of claim 7, further comprising emitting one or more audible beeps from the collection device (106) to indicate the start of the prepare to dry time period. 
Metoda prema patentnom zahtjevu 7, koja se dodatno sastoji od emitiranja jednog ili više zvučnih signala iz aparata za prikupljanje krvi (106) radi označavanja početka vremenskog razdoblja pripreme za sušenje.
The method of claim 7, further comprising emitting one or more audible beeps counting down the prepare to dry time period. 
Metoda prema patentnom zahtjevu 7, koja se dodatno sastoji od jednog ili više zvučnih signala kojima se odbrojava vremensko razdoblje pripreme za sušenje.
The method of claim 1, further comprising: initiating, in the blood collection device (106) immediately after the scrub time period has elapsed, a prepare to dry timer having a prepare to dry time period; during the prepare to dry period, performing a secondary wash of the patient at the proposed needle entry site; and counting down the prepare to dry period. 
Metoda prema patentnom zahtjevu 1, koja se dodatno sastoji od: pokretanja, u aparatu za prikupljanje krvi (106) neposredno po isteku vremenskog razdoblja čišćenja, tajmera za pripremu sušenja koji posjeduje vremensko razdoblje za pripremu sušenja; tijekom razdoblja pripreme za sušenje, obavljanja sekundarnog pranja pacijenta na predloženom mjestu uboda iglom; i odbrojavanja razdoblja pripreme za sušenje.
The method of claim 1, further comprising: after the disinfecting tissue step, automatically initiating in the blood collection device (106) a dry timer having a dry time period; and drying tissue of the patient at the proposed needle entry site during the dry time period. 
Metoda prema patentnom zahtjevu 1, koja se dodatno sastoji od: nakon koraka dezinfekcije tkiva, automatskog pokretanja u aparatu za prikupljanje krvi (106) tajmera za sušenje koji posjeduje vremensko razdoblje sušenja; i sušenja tkiva pacijenta na predloženom mjestu uboda iglom tijekom vremenskog razdoblja sušenja.
hyaluronic acid or a pharmaceutically acceptable salt thereof in an amount between 0.1% and 4% by weight; 
hijaluronske kiseline, ili njezine farmaceutski prihvatljive soli, u količini između 0,1% i 4%, težinski;
phosphate-buffered saline; and 
fosfatno puferirane fiziološke otopine; i
The composition according to claim 1, wherein the pharmaceutically acceptable salt is a sodium salt of hyaluronic acid. 
Pripravak u skladu s patentnim zahtjevom 1, naznačen time što je farmaceutski prihvatljiva sol natrijeva sol hijaluronske kiseline.
The composition according to claim 4 or 5, wherein the protein consists of resilin. 
Pripravak u skladu s patentnim zahtjevom 4 ili 5, naznačen time što se protein sastoji od rezilina.
preparing an aqueous solution of agarose and an aqueous solution of hyaluronic acid or a pharmaceutically acceptable salt thereof, wherein each solution has a gel point; 
pripravi vodene otopine agaroze i vodene otopine hijaluronske kiseline, ili njezine farmaceutski prihvatljive soli, gdje svaka otopina ima točku želiranja;
heating the solutions to temperatures near their gel points; 
grijanju otopina do temperatura blizu njihovih točaka želiranja;
mixing the solutions by homogenisation, to create a composition; and 
miješanju otopina homogeniziranjem, kako bi se dobio pripravak; i
adding salts by using a phosphate buffered saline (PBS) solution to the composition, thereby making the composition iso-osmolar with respect to blood plasma from a subject to be treated. 
dodavanju soli uz upotrebu fosfatno puferirane fiziološke otopine (PBS) u pripravak, čime se dobije pripravak izoosmolaran s krvnom plazmom iz subjekta kojeg treba liječiti.
an antibody antagonizing an immune pathway implicated in the inhibition of T cell activation, or a fragment thereof capable of reacting with the same antigen than its antibody counterpart, a polynucleotide coding therefore, or a vector comprising such a polynucleotide, wherein said antibody is a PD-1/PD-L1/PD-L2 antagonist, wherein said antibody is antagonizing either by binding the PD-1 receptor or by binding the PD-L1 or PD-L2 ligand; wherein said conjugate and the antibody or fragment thereof are not linked. 
antitijelo koje antagonizira imunološki put uključeno u inhibiciju aktivacije T stanice, ili njegov fragment koji može reagirati s istim antigenom kao njegovo odgovarajuće antitijelo, polinukleotid koji kodira, ili vektor koji sadrži takav polinukleotid, pri čemu je spomenuto antitijelo antagonist PD-1/PD-L1/PD-L2, pri čemu se spomenuto antitijelo antagonizira bilo vezanjem PD-1 receptora ili vezanjem PD-L1 ili PD-L2 liganda; pri čemu navedeni konjugat i njegovo antitijelo ili fragment nisu povezani.
A pharmaceutical composition for use in treating cancer in a subject comprising 
Farmaceutski pripravak za uporabu u liječenju raka kod subjekta koji sadrži
the antibody antagonizing an immune pathway implicated in the inhibition of T cell activation, or a fragment thereof is administrated by injection at a dose of 500 µg/kg or less, preferably at a dose of 100 µg/kg or less and most preferably at a dose of 50 µg/kg or less. 
antitijelo koje antagonizira imunološki put je uključeno u inhibiciju aktivacije T stanica, ili se njegov fragment daje injekcijom u dozi od 500 µg/kg ili manje, poželjno u dozi od 100 µg/kg ili manje, a najpoželjnije u dozi od 50 µg/kg ili manje.
contacting the mixture with a ligand capable of binding to a prion protein; and 
kontakt mješavine s ligandom koji ima sposobnost vezanja za protein priona; i
removing the ligand and proteins bound thereto from said mixture; and wherein the substantially water insoluble pharmacologically active agent is a taxane, an epothilone, a camptothecin, a colchicine, a geladanamycin, an amiodarone, a thyroid hormone, amphotericin, a corticosteroid, propofol, melatonin, cyclosporine, rapamycin, tacrolimus, a mycophenolic acid, ifosfamide, vinorelbine, vancomycin, gemcitabine, SU5416, thiotepa, bleomycin, or a diagnostic radiocontrast agent. 
uklanjanje liganda i proteina koji su na njega vezani iz navedene mješavine; pri čemu je u osnovi farmakološki aktivni agens netopiv u vodi taksan, epotilon, kamptotehin, kolhicin, geladanamicin, amiodaron, tiroidni hormon, kortikosteroid, propofol, melatonin, ciklosporin, rapamicin, takrolim, mikrofenolna kiselina, ifosfamid, vinorelbin, vankomicin, gemcitabin, SU5416, tiotepa, bleomicin, ili dijagnostički radiokontrastni agens.
removing the ligand and proteins bound thereto from the composition; and wherein the substantially water insoluble pharmacologically active agent is a taxane, an epothilone, a camptothecin, a colchicine, a geladanamycin, an amiodarone, a thyroid hormone, amphotericin, a corticosteroid, propofol, melatonin, cyclosporine, rapamycin, tacrolimus, a mycophenolic acid, ifosfamide, vinorelbine, vancomycin, gemcitabine, SU5416, thiotepa, bleomycin, or a diagnostic radiocontrast agent. 
uklanjanje liganda i za njega vezanih proteina iz pripravka; i pri čemu je u osnovi farmakološki aktivni agens netopiv u vodi taksan, epotilon, kamptotecin, kolhicin, geladanamicin, amiodaro, tiroidni hormon, amfotericin, kortikosteroid, propfol, melatonin, ciklosporin, rapamicin, takrolimus, mikofenolna kiselina, ifosfamid, vinorelbin, vankomicin, gemicitabin, SU5416, tiotepa, pleomicin ili dijagnostički radiokontrastni agens.
A composition comprising nanoparticles comprising albumin and a substantially water insoluble pharmacologically active agent, further comprising a ligand capable of binding to a prion protein, wherein the substantially water insoluble pharmacologically active agent is a taxane, an epothilone, a camptothecin, a colchicine, a geladanamycin, an amiodarone, a thyroid hormone, amphotericin, a corticosteroid, propofol, melatonin, cyclosporine, rapamycin, tacrolimus, a mycophenolic acid, ifosfamide, vinorelbine, vancomycin, gemcitabine, SU5416, thiotepa, bleomycin, or a diagnostic radiocontrast agent. 
Pripravak koji obuhvaća nanočestice koje sadrže albumin i u osnovi farmakološki aktivni agens netopiv u vodi, nadalje sadrži ligand sposoban za vezanje na prion protein, pri čemu je u osnovi farmakološki aktivni agens netopiv u vodi taksan, epotilion, kamptotehtin, kolcihin, geladanamicin, amiodaron, tiroidni hormon, smfotericin, kortikosteroid, propofol, melatonin, ciklosporin, rapamicin, takrolim, mikofenolna kiselina, ifosfamid, vinorelbin, vankomicin, gemicitabin, SU5416, tiotepa, bleomicin, ili dijagnostički agens radiokontrasta.
The method or the composition of claim 5, wherein the peptide is DVR, YVHEA, AMN31, SYA, or D4. 
Postupak ili pripravak sukladno zahtjevu 5, pri čemu je peptid DVR, YVHEA, AMN31, SYA, ili D4.
The method or the composition of claim 8, wherein the antibody is 3F4, 6H4, 16A18, ICSM-4, or ICSM-10. 
Postupak ili pripravak sukladno zahtjevu 8, pri čemu je antitijelo 3F4, 6H4, 16A18, ICSM-4 ili ICSM-10.
The method or the composition of any one of claims 1 to 4, wherein the ligand is a polymeric material that binds to a prion protein. 
Postupak ili pripravak sukladno bilo kojem od zahtjeva 1 do 4, pri čemu je ligand polimerni materijal koji se veže za protein priona.
The method or the composition of claim 10, wherein the polymeric material comprises an amino group, a phenyl group, or a methacrylate backbone. 
Postupak ili pripravak sukladno zahtjevu 10, pri čemu polimerni materijal obuhvaća amino skupinu, fenilnu skupinu, ili metakrilatnu kralježnicu.
A pupa comprising a recombinant baculovirus and/or a bacmid derived from Autographa californica multicapsid nucleopolyhedrovirus (AcMNPV), wherein the pupa belongs to the genus Trichoplusia. 
Kukuljica koja sadrži rekombinantni bakulovirus i/ili bakmid koji potječe od Autographa californica multicapsid nucleopolyhedrovirus (AcMNPV), naznačena time što kukuljica pripada rodu Trichoplusia.
The pupa according to claim 1, wherein the recombinant baculovirus and/or bacmid comprises a nucleic acid sequence encoding a recombinant protein. 
Kukuljica prema patentnom zahtjevu 1, naznačena time što rekombinantni bakulovirus i/ili bakmid sadrži sekvencu nukleinske kiseline koja kodira rekombinantni protein.
a nucleic acid sequence having a sequence identity of at least 70% with the nucleotide sequence indicated in any of SEQ ID NOs: 1-5 and encoding a protein able to function as a transcriptional regulator in a recombinant baculovirus; 
sekvencu nukleinske kiseline koja ima identičnost od najmanje 70 % s nukleotidnom sekvencom navedenom u bilo kojoj od SEQ ID NOs: 1-5 i kodira protein koji može funkcionirati kao regulator transkripcije u rekombinantnom bakulovirusu;
a nucleic acid sequence encoding an amino acid sequence having a sequence similarity of at least 70% with the amino acid sequence indicated in any of SEQ ID NOs: 6-9 and able to function as a transcriptional regulator in a recombinant baculovirus. 
sekvencu nukleinske kiseline koja kodira sekvencu aminokiseline koja ima sličnost sekvence od najmanje 70 % sa sekvencom aminokiseline navedenom u bilo kojoj od SEQ ID NOs: 6-9 i koja može funkcionirati kao regulator transkripcije u rekombinantnom bakulovirusu.
A pupa comprising a nucleic acid sequence that allows for the expression above endogenous levels of the proteins IE-1, IE-0 and/or fragments thereof functioning as transcriptional regulators above endogenous levels obtained during baculovirus infection and a recombinant homologous region (hr) operably linked to any promoter that is suitable for driving the expression of a recombinant protein, wherein the pupa belongs to the genus Trichoplusia, wherein the nucleic acid sequence that allows for the expression of the proteins IE-1, IE-0 and/or fragments thereof is selected from the group consisting of: 
Kukuljica koja sadrži sekvencu nukleinske kiseline koja omogućava ekspresiju iznad endogenih razina proteina IE-1, IE-0 i/ili njihovih fragmenata koji djeluju kao transkripcijski regulatori iznad endogenih razina dobivenih tijekom bakulovirusne infekcije i rekombinantnu homolognu regiju (hr) operativno povezanu s bilo kojim promotorom koji je pogodan za pokretanje ekspresije rekombinantnog proteina, pri čemu kukuljica pripada rodu Trichoplusia, naznačena time što je sekvenca nukleinske kiseline koja omogućava ekspresiju proteina IE-1, IE-0 i/ili njihovih fragmenata odabrana iz skupine koja sadrži:
The pupa according to any one of claims 2 to 4, wherein the promoter that drives the expression of said recombinant protein is, selected from the group of nucleic acids comprising: 
Kukuljica prema bilo kojem od patentnih zahtjeva 2 do 4, naznačena time što je promotor koji pokreće ekspresiju navedenog rekombinantnog proteina, odabran iz skupine nukleinskih kiselina koja sadrži:
a nucleic acid sequence able to function as a promoter in a recombinant baculovirus and having a sequence identity of at least 70% with the nucleotide sequence indicated in any of SEQ ID NOs: 10-14; and/or wherein the recombinant homologous region (hr) is the sequence indicated in SEQ ID NO: 21 (hr1). 
sekvencu nukleinske kiseline koja može funkcionirati kao promotor u rekombinantnom bakulovirusu i koja ima identičnost sekvence od najmanje 70 % s nukleotidnom sekvencom navedenom u bilo kojoj od SEQ ID NOs: 10-14; i/ili pri čemu je rekombinantna homologna regija (hr) sekvenca navedena u SEQ ID NO: 21 (hr1).
The pupa according to any one of claims 2 to 5, wherein the nucleic acid sequence that comprises combinations of recombinant promoters, sequences encoding transcriptional regulators and enhancer regions are selected from the group comprising SEQ ID NOs: 15-20. 
Kukuljica prema bilo kojem od patentnih zahtjeva 2 do 5, naznačena time što su sekvenca nukleinske kiseline koja sadrži kombinacije rekombinantnih promotora sekvence koje kodiraju transkripcijske regulatore i pojačivačke regije odabrane iz skupine koja sadrži SEQ ID NOs: 15-20.
The pupa according to any one of claims 3 to 6, wherein the pupa further comprises a nucleic acid sequence encoding a recombinant protein. 
Kukuljica prema bilo kojem od patentnih zahtjeva 3 do 6, naznačena time što kukuljica nadalje sadrži sekvencu nukleinske kiseline koja kodira rekombinantni protein.
Inoculating the pupa of step (a) with a recombinant baculovirus derived from Autographa californica multicapsid nucleopolyhedrovirus (AcMNPV); 
inokuliranje kukuljice iz koraka (a) s rekombinantnim bakulovirusom koji potječe od Autographa californica multicapsid nucleopolyhedrovirus (AcMNPV);
Providing a pupa contained in a silk cocoon; 
osiguravanje kukuljice sadržane u svilenoj čahuri;
Transfecting the pupa of step (a) with a bacmid suitable for producing a recombinant baculovirus derived from Autographa californica multicapsid nucleopolyhedrovirus (AcMNPV); 
transfekciju kukuljice iz koraka (a) s bakmidom pogodnim za proizvodnju rekombinantnog bakulovirusa koji potječe od Autographa californica multicapsid nucleopolyhedrovirus (AcMNPV);
Incubating the inoculated pupa of step (b) for a period of time sufficient for the recombinant baculovirus is produced; and 
inkubiranje inokulirane kukuljice iz koraka (b) tijekom vremena koje je dovoljno za proizvodnju rekombinantnog bakulovirusa; i dobivanje kukuljica koje sadrže rekombinantni bakulovirus.